Free tool
FAERS Monitor: Zymaxid
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022548 or its brand name (Zymaxid, Gatifloxacin). Reports on generic versions are filed under their own applications.
Reports
1,785
Serious
1,437
81% of reports
Hospitalization
689
Death reported
106
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- hypoglycaemia151
- hyperglycaemia96
- anaphylactic reaction85
- drug intolerance83
- drug ineffective79
- diarrhoea71
- eye pain68
- dizziness58
- off label use56
- dyspnoea55
- rash55
- nausea50
- chronic kidney disease47
- renal failure47
- blood glucose increased46
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 299 |
| 2005 | 309 |
| 2006 | 119 |
| 2007 | 42 |
| 2008 | 47 |
| 2009 | 37 |
| 2010 | 40 |
| 2011 | 55 |
| 2012 | 69 |
| 2013 | 41 |
| 2014 | 48 |
| 2015 | 49 |
| 2016 | 56 |
| 2017 | 62 |
| 2018 | 77 |
| 2019 | 100 |
| 2020 | 62 |
| 2021 | 51 |
| 2022 | 53 |
| 2023 | 40 |
| 2024 | 39 |
| 2025 | 41 |
| 2026 | 49 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,374 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hypoglycaemiaSignal | 151 | 36.8 | 31.6 | 5,218 |
| hyperglycaemiaSignal | 96 | 31.1 | 25.6 | 2,766 |
| anaphylactic reactionSignal | 85 | 18.2 | 14.7 | 1,362 |
| eye painSignal | 68 | 14.2 | 11.3 | 824 |
| drug intoleranceSignal | 83 | 10.1 | 8.2 | 677 |
| chronic kidney diseaseSignal | 47 | 7.3 | 5.5 | 250 |
| renal failureSignal | 47 | 4.2 | 3.1 | 111 |
| blood glucose increasedSignal | 46 | 2.9 | 2.2 | 55 |
| rash | 55 | 1.5 | 1.1 | 8 |
| dizziness | 58 | 1.4 | 1.1 | 6 |
| diarrhoea | 71 | 1.3 | 1.0 | 5 |
| dyspnoea | 55 | 1.1 | 0.9 | 1 |
| off label use | 56 | 0.8 | 0.6 | 4 |
| nausea | 50 | 0.7 | 0.6 | 4 |
| drug ineffective | 79 | 0.7 | 0.6 | 10 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.